跳至主要内容
临床试验/NCT06156748
NCT06156748已完成不适用

CT Imaging for Guiding Postoperative Adjuvant Transarterial Chemoembolization for Hepatocellular Carcinoma

Zhujiang Hospital1 个研究点 分布在 1 个国家目标入组 1,770 人开始时间: 2019年10月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,770
试验地点
1
主要终点
Overall survival

研究概览

简要总结

Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of candidates are lacking. The present study aimed to evaluate whether CT imaging can provide more value for predicting benefit from PA-TACE.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • CT scans acquired no more than one month before surgery
  • Confirmation of HCC diagnosis by pathological examination
  • Curative surgical resection

排除标准

  • Prior antitumor treatment
  • Macrovascular thrombosis or metastasis
  • Perioperative mortality
  • Unqualified image artifacts
  • Tumor rupture
  • MVI status not reported

结局指标

主要结局

Overall survival

时间窗: the date of hepatectomy to the last follow-up or until death, whichever came first, assessed up to 120 months.

Overall survival was calculated from the date of hepatectomy to the last follow-up or until death, whichever came first.

次要结局

未报告次要终点

研究者

发起方
Zhujiang Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Quan Xianyue

Academic Head of Department of Radiology

Zhujiang Hospital

研究点 (1)

Loading locations...

相似试验